Business Wire
24 Mar 2026, 20:00 UTC · 25w ago
Verdict
Headline leans bearish. We score BSX −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Boston Scientific disclosed disappointing U.S. EP sales and issues, causing shares to drop approximately 17.6% on February 4, 2026.
So whatDirect revenue misses in a core business segment typically lead to immediate valuation downgrades and lower growth expectations.
More negative than 98% of claims this week
Levi & Korsinsky, LLP has initiated a securities class action lawsuit against Boston Scientific Corporation.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 73% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities class action lawsuit following a significant stock price drop and disappointing sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−36.1%
Price agrees with the score
$43.55 vs $68.15 close before publication (Mar 24) · not market-adjusted
BSX chart →
